The Origin of our Success Story
Mammalian manufacturing facility: Biberach, Germany
As Europe’s largest biopharmaceutical multi-product plant for mammalian cell culture, our Biberach site offers the development and manufacture of therapeutic proteins and antibodies in one pilot plant and two large-scale manufacturing facilities. The site began operations in 1983, marking one of the major milestones for Boehringer Ingelheim BioXcellence™.
The single-use plant that houses bioreactors from 100 L to 500 L as well as a disposable downstream processing facility provides the entire value chain from research and development to production. Fed-batch processes in large-scale bioreactors of 15,000 L are a core technology, but Biberach also offers perfusion processes in 2,000 L bioreactors established within the commercial facilities.
Tailor-made services for your success.
| History: | Boehringer Ingelheim’s first plant started in 1983 and became the largest in Europe. |
| Employees: | more than 2,000 |
| Standout Characteristics: | Center of excellence for cell line development (BI-HEX® CHO-K1) |
| Technology: | Mammalian Cell Culture Stainless Steel and Single-Use Bioreactors |
| Capabilities: |
Cell line and process development Clinical and commercial |
| Track Record: |
Launch site for almost all of our customers commercial mammalian products Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins 25+ years’ experience in clinical Fill & Finish 15+ years’ experience in manufacturing clinical and commercial cell banks 60 different biologics and about 80 different processes for manufacturing pre-clinical and clinical material 200 master, working and bioassay cell banks |
